Disease-modifying therapy aids cognition in multiple sclerosis

Maria Pia Amato^{1

2}, Lauren B Krupp³

Affiliations

¹ Department NEUROFARBA, University of Florence, Florence, Italy. mariapia.amato@unifi.it.
² IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy. mariapia.amato@unifi.it.
³ Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA.

Comment

Maria Pia Amato et al. Nat Rev Neurol. 2020 Oct.

. 2020 Oct;16(10):525-526.

doi: 10.1038/s41582-020-0383-x.

Maria Pia Amato^{1

2}, Lauren B Krupp³

¹ Department NEUROFARBA, University of Florence, Florence, Italy. mariapia.amato@unifi.it.
² IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy. mariapia.amato@unifi.it.
³ Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA.

No abstract available

Comment on

Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.
Landmeyer NC, Bürkner PC, Wiendl H, Ruck T, Hartung HP, Holling H, Meuth SG, Johnen A. Landmeyer NC, et al. Neurology. 2020 Jun 2;94(22):e2373-e2383. doi: 10.1212/WNL.0000000000009522. Epub 2020 May 19. Neurology. 2020. PMID: 32430312

1. Benedict, R. H. & Zivadinov, R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat. Rev. Neurol. 7, 332–342 (2011). - DOI
1. Amato, M. P., Krupp, L. B., Charvet, L. E., Penner, I. & Till, C. Pediatric multiple sclerosis: cognition and mood. Neurology 87, S82–S87 (2016). - DOI
1. Sotirchos, E. S. et al. Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis. Mult. Scler. 26, 312–321 (2020). - DOI
1. Amato, M. P. et al. Association of neocortical volume changes with cognitive deterioration in relapsing–remitting multiple sclerosis. Arch. Neurol. 64, 1157–1161 (2007). - DOI
1. Landmeyer, N. C. et al. Disease-modifying treatments and cognition in relapsing–remitting multiple sclerosis: a meta-analysis. Neurology 94, e2373–e2383 (2020). - DOI